Quick Answer
Lyell Immunopharma, Inc. reported Operating Income Loss of -$269.40 million for the year ending 2025.
- Lyell Immunopharma, Inc. showed an increase of +24.9% in Operating Income Loss from 2024 to 2025.
- This data is from Lyell Immunopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$102.57 million | Q3 2020: -$36.84 million | Q1 2021: -$55.37 million | Q2 2021: -$62.71 million | Q3 2021: -$49.16 million | Q1 2022: -$68.58 million | Q2 2022: -$37.26 million | Q3 2022: -$66.44 million | Q1 2023: -$62.56 million | Q2 2023: -$65.91 million | Q3 2023: -$59.04 million | Q1 2024: -$55.58 million | Q2 2024: -$51.53 million | Q3 2024: -$50.51 million | Q1 2025: -$57.37 million | Q2 2025: -$47.14 million | Q3 2025: -$37.25 million.
- Over the full 7 years of available data (2019 to 2025), Lyell Immunopharma, Inc.'s Operating Income Loss has declined by 163.9%.
- Historical annual values: Fiscal year 2025: -$269.40 million | Fiscal year 2024: -$358.76 million | Fiscal year 2023: -$247.01 million | Fiscal year 2022: -$187.06 million | Fiscal year 2021: -$214.78 million | Fiscal year 2020: -$211.94 million | Fiscal year 2019: -$102.09 million.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: